Target intelligence / Profile preview

Gametocyte surface protein P230 (Pfs230)

Target
Pfs230
Molecular classification
Other
01

Overview

Gametocyte surface protein P230 (Pfs230) is a large, cysteine-rich peripheral membrane protein belonging to the 6-cysteine (6-cys) family in Plasmodium falciparum. It is expressed on the surface of gametocytes and gametes, where it forms a complex with the glycosylphosphatidylinositol (GPI)-anchored protein Pfs48/45. Pfs230 plays a critical role in the sexual reproduction stage of the malaria parasite, specifically mediating male gamete exflagellation, interaction with host erythrocytes, and male-female gamete fusion during fertilization in the mosquito midgut. Because of its essential role in parasite transmission, Pfs230 is a leading target for malaria transmission-blocking vaccines (TBVs). Vaccines such as Pfs230D1-EPA and multi-stage candidates like ProC6C aim to elicit high titers of transmission-blocking antibodies in the human host. When a mosquito ingests these antibodies during a blood meal, they bind to Pfs230 on the gamete surface and, in a complement-dependent manner, inhibit fertilization and subsequent oocyst development, thereby halting the transmission cycle of malaria.

Other names
Pfs230PF230S230Gametocyte surface protein P230Transmission-blocking target antigen Pfs230
02

Mechanism of action

Active immunization with Pfs230-based vaccines elicits host antibodies that are ingested by mosquitoes during a blood meal. These antibodies, along with host complement, bind to Pfs230 on the surface of gametes in the mosquito midgut, blocking gamete fusion, fertilization, and subsequent development into oocysts, thereby preventing malaria transmission. Passive administration of monoclonal antibodies like LMIV230-01 similarly blocks transmission by targeting conserved epitopes on Pfs230.

03

Biological functions

Immune responseOther
04

Disease associations

Infection
05

Safety considerations

Injection site reactions and systemic reactogenicity (fever, headache, fatigue) associated with vaccine adjuvants like Alhydrogel or AS01Rapid decay of antibody titers requiring booster doses to maintain transmission-blocking efficacyPotential for immune evasion due to genetic polymorphisms in the target antigen
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

Antibody titer (ELISA)Transmission-reducing activity (TRA)Transmission-blocking activity (TBA)Standard membrane feeding assay (SMFA)Direct skin feeding assay (DSF)

Beyond the preview

Go deeper on Gametocyte surface protein P230 (Pfs230).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gametocyte surface protein P230 (Pfs230).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call